Latest Intelligence on Manufacturers in Europe

Published within

« | 1 | 2 | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Vaccines: Intercell buys Iomai

Intercell has acquired Iomai for $189 million, in a deal motivated by the Austrian company's desire to gain ownership of Iomai's traveler's diarrhea vaccine and transdermal delivery technology. With the potential to deliver both vaccine and adjuvant, independently, through Iomai's transdermal patch, Intercell's development of its proprietary adjuvant IC31 may also benefit from the technology.

Published By Datamonitor
13 May 2008
Expert View
Expert View

Roche looks to maximize Genentech potential

Roche has initiated efforts to acquire all outstanding shares in Genentech for approximately $43.7 billion, having purchased 55.9% of the company in 1990. While Genentech has historically operated independently from its parent company, it remains to be seen whether the merger will damage an operating structure which has allowed the biotech firm to drive Roche's growth performance in recent years.

Published By Datamonitor
23 Jul 2008
CommentWire
CommentWire

Nabi: pharmaceutical giants should cough up for smoking vaccine

Positive interim results, assessing the antibody response and safety of a 400mcg, six-dose immunization schedule of Nabi Biopharmaceuticals' NicVAX, provide a new indication of the vaccine's potential to treat nicotine addiction and prevent smoking relapse. These results make the product a more attractive licensing proposition as Nabi gears up to initiate pivotal Phase III trials.

Published By Datamonitor
25 Jul 2008
CommentWire
CommentWire

Wyeth: Big Pharma continues its shopping spree

The current economic environment has paved the way for leading pharmaceutical firms to sweep in and buy up smaller players, highlighted by Wyeth's potential acquisition of Crucell and Merck & Co's strategy to aggressively look for targets in 2009. An increasing number of pharmaceutical majors are likely to use this approach to strengthen their biologic portfolios and access novel pipeline drugs.

Published By Datamonitor
09 Jan 2009
Expert View
Expert View

Biosimilars in the EU: delivering the goods?

In January, leading pharmaceutical experts attended the 2009 Forum Institute seminar on biosimilars, and the challenges involved in their successful development and launch. While the main focus of the meeting the biosimilars market in the EU, it was widely agreed that developments in the US, and President Obama's handling of the generic biotech issue, will be the defining issue of 2009 and beyond.

Published By Datamonitor
05 Mar 2009
Expert View
Expert View

ESMO 2009: new lease of life for Vectibix in colorectal cancer?

Results from two Phase III studies presented at the European Society for Medical Oncology Congress 2009 show statistically significant benefits via the addition of Vectibix to both first- and second-line chemotherapy for wild-type KRAS metastatic colorectal cancer. These positive data could help Vectibix to overcome Erbitux's first-to-market status and usurp its current position.

Published By Datamonitor
30 Sep 2009
Expert View
Expert View

ESMO 2009: denosumab as potential new treatment option for skeletal-related events in cancer

Statistically significant positive results in two Phase III studies investigating denosumab in solid tumors and multiple myeloma have added to the ongoing excitement around Amgen's investigational product. These results, added to an impending decision from the FDA regarding approval, mean that a new treatment option for bone metastases in cancer patients could be on the market within months.

Published By Datamonitor
30 Sep 2009
Expert View
Expert View

FIGO 2009: focus moves towards cervical cancer and overactive bladder

Among the key developments at this year's International Federation of Gynecology and Obstetrics meeting, pharmaceutical companies aimed to improve awareness of overactive bladder. Elsewhere, the reduction of mortality due to cervical cancer emerged as a key theme among delegates, with discussions of vaccine strategies not only in the developed world but also in developing countries.

Published By Datamonitor
13 Oct 2009
CommentWire
CommentWire

Antigenics: Oncophage EU marketing application likely to fail

Antigenics is seeking EU approval for Oncophage in early-stage renal cell carcinoma. Despite there currently being no approved drugs for the post-surgical treatment of adjuvant kidney cancer in the EU or US, Oncophage's application is expected to fail. Antigenics will have to provide more robust evidence of Oncophage's efficacy if it wishes to gain approval in the lucrative US and EU markets.

Published By Datamonitor
22 Oct 2009
CommentWire
CommentWire

Genentech/Biogen Idec: ocrelizumab encouraging in trials but lacks differentiation

Partners Genentech and Biogen Idec have announced positive results from the Phase III STAGE trial of ocrelizumab in rheumatoid arthritis. The positive data come as no real surprise and Datamonitor expects that ocrelizumab will launch for rheumatoid arthritis. However, the drug will suffer from a lack of differentiation from other B cell therapies.

Published By Datamonitor
11 Dec 2009

« | 1 | 2 | » »|

No help is available.